The Washout Is the Setup: A Sandbagged 2026 Floor and a Cleared Deck Turn the Risk/Reward

Results vs. Consensus

This was the most consequential UnitedHealth print in years, and almost none of what mattered was in the fourth quarter itself. The Q4 numbers were a near-zero GAAP quarter by construction: management ran a $2.8 billion pre-tax "kitchen-sink" charge through the period, pushing GAAP EPS to a single penny and earnings from operations to $380 million from $7.8 billion a year ago. Strip the charge and adjusted EPS was $2.11, a hair above the ~$2.09 to $2.10 the Street carried in, on revenue of $113.2 billion that landed a touch light against a ~$113.7 billion consensus. For the full year, adjusted EPS of $16.35 cleared the company's own raised "at least $16.25" floor and edged Street by a few cents. By the narrow yardstick of the printed quarter, this was a slight beat on the bottom line and a slight miss on the top.

The market did not care about the quarter. It cared about the 2026 outlook, and on the metric the stock keys off the outlook was a genuine disappointment. Revenue is guided to more than $439.0 billion, roughly a 2% decline from 2025's $447.6 billion, against a Street that had modeled ~$454.6 billion. That is the first annual revenue contraction for this franchise in more than three decades, and it walks back the "return to growth in 2026" narrative management itself had floated through the middle of last year. Adjusted EPS is guided to greater than $17.75, only ~8.6% above a depressed $16.35 base and well short of the ~$20 recovery the market had built into estimates after the Q3 stabilization. The stock fell 19.6%.

Year-over-Year Comparison (Q4)

Full-Year 2025 Summary

Quality of Beat/Miss

• Revenue: Full-year revenue of $447.6B grew a broad +11.8%, driven by UnitedHealthcare's 16% rise on Medicare Advantage membership and Inflation Reduction Act Part D pricing mechanics, plus Optum Rx's 16% on scripts and specialty mix. Revenue was never the problem. The shock is the forward number: 2026 guided down ~2% on what management calls "planned right-sizing," a top line deliberately shrunk to restore margin. The miss against consensus is real, but it is a strategic choice, not a demand failure.
• Margins: Adjusted full-year MCR of 88.9% was +340bp YoY, the same Medicare-funding-cut and cost-trend story that has defined the cycle. The constructive piece is forward: 2026 MCR guided to 88.8% ±50bp, a ~30bp improvement on repricing, with ~40bp of operating-margin expansion at each of UnitedHealthcare and Optum. Full-year medical reserve development was $140M favorable. The margin trough is being called for 2025; 2026 is guided to inflect, modestly.
• EPS: The 69% YoY Q4 adjusted-EPS drop and the 41% full-year drop are operational, driven by the Optum Health collapse and the Medicare/Medicaid funding squeeze. The GAAP-to-adjusted bridge is wide this quarter ($2.10 of charge adjustments separate $0.01 GAAP from $2.11 adjusted), but the components are well-disclosed and mostly non-cash. Diluted share count fell to 910–911M (from 927–929M PY) on the $5.5B of buybacks completed before the pause. The number is depressed; its construction is clean.

Segment Performance

The full-year segment picture is the clearest map of where the damage concentrated and where the 2026 repair is aimed. UnitedHealthcare's operating margin fell to 2.7% from 5.2% on funding cuts and trend, but the segment is the one with the cleanest 2026 lever (January repricing). Optum is the harder story: total Optum operating margin compressed to 3.5% from 6.6%, and within it Optum Health swung to a full-year operating loss of $(278)M from $7.8B of earnings a year ago, the single most damaging line in the franchise. The fourth quarter is where the charge landed, so Q4 segment GAAP earnings are distorted; the table below shows both full-year and Q4 to separate the run-rate from the sweep.

UnitedHealthcare: A 2.7% Margin and the Cleanest 2026 Lever

UnitedHealthcare full-year revenue grew 16% to $344.9 billion serving 49.8 million people (up 415,000), but operating earnings fell to $9.4 billion from $15.6 billion and operating margin compressed to 2.7% from 5.2%, the damage attributed squarely to Biden-era Medicare funding reductions, Inflation Reduction Act impacts, and elevated cost trend. The fourth quarter was the seasonal trough: just $0.3 billion of operating earnings on a 0.4% margin. Within the book, Medicare & Retirement revenue grew 23% to $171.3 billion (Medicare Advantage membership, including complex Medicaid populations, up 755,000 for the year), Community & State grew 17% to $94.4 billion (people served down 55,000 on state eligibility redeterminations), and Employer & Individual was roughly flat at $79.2 billion (down 80,000 served as self-funded growth offset fully-insured and individual attrition).

"We closed the year with medical care patterns in each business in line with our updated outlook and ultimately supportive of our pricing decisions for 2026... the 2025 medical cost trend was in line with our expectation of approximately 7.5% and supports our 2026 trend expectation of 10%." — Timothy Noel, UnitedHealthcare CEO

The 2026 plan is explicit and aggressive. Management guided UnitedHealthcare revenue to more than $335 billion (down from $344.9B) and operating earnings to more than $10.8 billion, a ~3.2% margin and ~40bp of improvement, achieved by deliberately shedding 2.3 to 2.8 million medical members: a 1.3–1.4 million total Medicare Advantage contraction (greater than originally planned as competitive annual-enrollment shopping intensified), 565,000–715,000 in Medicaid on eligibility changes and a state exit, and 850,000–550,000 net in commercial as risk lives fall and self-funded grows. Management expects ~50bp of Medicare margin recovery and ~13% adjusted operating-earnings growth across UnitedHealthcare.

Assessment: This is the segment doing the heavy lifting on the 2026 inflection, and the lever is the cleanest in the company because January repricing is a known, mechanical event rather than a multi-year build. Trading 2.3 to 2.9 million members for 40bp of margin is the right discipline, and the candor that the 2026 trades favor margin over membership is exactly the posture that was missing in 2024. The catch is the same one that hangs over the whole print: a repriced book is a shrinking book, and even here management concedes margins stay "slightly below our historical range until 2027." The bleeding has stopped and the repricing is mechanical, which is why this is the part of the story we are most willing to underwrite.

Optum Health: A $2.8 Billion Q4 Loss and a Reset Baseline

Optum Health is the centerpiece of the damage and the reset. Full-year revenue fell 3% to $102.0 billion and the segment swung to a full-year operating loss of $(278)M from $7.8 billion of earnings in 2024; adjusted full-year earnings were $2.3 billion against $7.9 billion a year ago. The fourth quarter was catastrophic on the surface: a reported operating loss of $(2.8) billion, a (10.9)% margin, as the bulk of the restructuring charge and the loss-contract reserve landed here. Stripping the charge, management put the segment's clean exit-rate adjusted earnings at roughly $1.5 billion, well below the ~$3 billion run-rate implied at Q3, a downward reset that was the single most alarming disclosure in the Q&A. The 2026 guide is for revenue greater than $91 billion (after Optum Financial Services moves out to Optum Insight), operating earnings greater than $2.2 billion, a ~2.4% margin, with fully-accountable patients cut to ~4.1 million.

"Excluding restructuring and the move of Optum Financial, our adjusted earnings are now approximately $1.5 billion which is our new baseline that we will continue to build off of in the future... we've narrowed our affiliated network by nearly 20% since this time last year... we have streamlined our risk membership by approximately 15%." — Krista Nelson, Optum Health COO

The remediation is the most concrete it has been: a ~20% narrowing of the affiliated network, a ~15% cut to risk membership (dropping unaligned PPO contracts and de-delegating where contracts could not be reached), consolidation onto three strategic electronic medical records from 18, and a refocus on integrated value-based care in markets where the model works. Management reaffirmed the 6–8% long-term margin target and pointed to mature cohorts and high-performing markets (a Texas market serving 750,000 patients already inside the target range) as proof of concept.

Assessment: A $2.8 billion quarterly loss is shocking on its own terms, and the reset of the clean baseline to ~$1.5 billion is the part of the print that genuinely lowers the multi-year earnings ceiling. But there is a version of this that is constructive: the loss is mostly the charge, the loss contracts are now reserved rather than recurring, the book is right-sized to ~4.1 million accountable patients, and 2026 guides to a positive ~2.4% margin off a clean base. We treat Optum Health as a 2027 call option, not a 2026 contributor, exactly as we did at Q3. What changed is that the deck is now swept, so the option is on a clean baseline rather than a deteriorating one. That is a better starting point, even if the absolute level is lower.

Optum Insight: Steady, Re-Platforming, Now Absorbing Optum Financial

Optum Insight full-year revenue rose 4% to $19.4 billion with operating earnings of $2.6 billion (adjusted $3.7 billion, a ~19% adjusted margin), the dip from 2024 reflecting new-product-launch costs and growth investment. Contract backlog declined to $31.1 billion from $32.1 billion at Q3 and $32.8 billion at the prior year-end, a soft signal worth watching. The structural change for 2026 is the realignment of Optum Financial Services into Optum Insight, which on a recast basis lifts the segment's adjusted earnings (Optum Financial contributed ~$837M of the recast), with 2026 revenue guided above $21 billion and a ~22.6% margin.

"Our traditional services in OptumInsight have to evolve to AI-first services, then to products and eventually to platforms... integrating OptumReal's AI driven revenue cycle solutions with Optum Financial Services payment and financing capabilities has the potential to transform health care transactions, moving the industry from post service reconciliation to real time point of care approval." — Patrick Conway, Optum CEO

Assessment: Insight remains the steadiest part of Optum and the cleanest beneficiary of the AI-first pivot, and folding Optum Financial in creates a genuinely interesting closed-loop revenue-cycle-plus-payments asset. But the declining backlog is a yellow flag for a business sold on multi-year visibility, and at ~7% of total revenue Insight is still too small to move the consolidated needle. It is improving ballast with optionality, not a 2026 thesis driver.

Optum Rx: The Growth Engine Holds, Margin Mix Caps It

Optum Rx was the bright spot: full-year revenue grew 16% to $154.7 billion on pharmacy services and new-and-existing client volume, operating earnings rose to $7.2 billion from $5.8 billion, and adjusted scripts grew to 1.66 billion from 1.62 billion. The fourth quarter delivered $2.9 billion of reported operating earnings (the segment carries a favorable charge allocation). Management cited more than 800 new client relationships from the selling season, with new wins more than offsetting the attrition flowing from UnitedHealthcare's membership contraction, and reaffirmed the move to 100% rebate pass-through (over 95% of customers electing it for 2026). The 2026 guide is for revenue above $150.5 billion, operating earnings above $6.25 billion (~4.2% adjusted margin, +20bp), and scripts above 1.52 billion.

"Strong selling season in 2026 combined with retention allowed us to backfill... about half, maybe more than half, of the membership loss from UHC. And so that puts us in a nice position to deliver a modest 2% earnings growth in 2026... why did those 800 new clients choose OptumRx? Affordability, transparency, and execution." — Wayne DeVeydt, CFO

Assessment: Rx is doing precisely what a healthy PBM should, winning clients and growing scripts while the rest of the franchise resets, and the transparency push positions it ahead of regulatory pressure rather than behind it. But its margin is structurally capped by drug mix and full rebate pass-through, so a 16%-revenue-growth business contributes only mid-single-digit earnings growth. The 2026 script guide of above 1.52 billion (down from 1.66 billion) reflects the UnitedHealthcare attrition flowing through. Rx is the dependable ballast that keeps the franchise relevant in pharmacy; it is not the engine that restores enterprise margin.

Key Topics & Management Commentary

Overall Management Tone: The posture was disciplined, forward-leaning, and conspicuously conservative on the numbers, a clear continuation of the under-promise reset that began at Q2. Management framed 2026 as "a year of focus and execution" and wrapped every segment figure in "greater than" language, while leaning hard on the transparency and independent-review narrative to rebuild credibility. The notable shift from Q3 is that the new CFO now owns a full-year guide rather than deferring to consensus, and he set it visibly low; the call's only soft moments were the Optum Health Q4 volatility, which management conceded was "slightly disappointing," and a firm refusal to discuss 2027 in any quantified way given the same-day CMS advance notice.

1. The 2026 Guide as a Deliberately Low Floor

The entire print turns on how to read the >$17.75 adjusted-EPS and >$439B revenue guide. Taken at face value it is a disappointment: ~8.6% EPS growth off a depressed base and the first revenue decline in three decades. Read structurally, it is a floor authored by a finance team rebuilding credibility after a year of broken guidance, with revenue right-sized down so the base is clean and beatable.

"Looking to 2026, we expect adjusted earnings per share of greater than $17.75 for growth of at least 8.6%. Our initial outlook reflects measured growth across all four of our reporting business segments... We expect 2026 to be a year of focus and execution." — Stephen Hemsley, Chairman & CEO

The "greater than" framing runs through every line of the data table: revenue greater than $439B, operating earnings greater than $24B, EPS greater than $17.75, cash flow greater than $18B. The CFO described the outlook as "durable performance improvement and margin expansion through greater operating discipline and precise execution," language built to be cleared rather than chased.

Assessment: A new finance team's first full-year guide after a credibility crisis is almost always sandbagged, and this one carries every tell: "greater than" qualifiers, a right-sized clean base, and a margin path (88.8% MCR, +40bp segment margins) that is already conservative against the repricing math. The market read the headline; we read the construction. A beatable floor at a washed-out price is the setup we have been waiting for.

2. The $2.8 Billion Kitchen-Sink Charge, Dissected

The charge is the mechanism by which the deck got cleared, and management walked through it with unusual specificity. The $2,878M pre-tax total nets to $1,622M and $1.78/share after a $1,256M tax benefit, and is "largely non-cash and primarily related to actions within Optum."

"This net charge has three primary components. First, a true up for all remaining cyber attack related activities, including approximately $800 million... Second, a net gain of about $440 million related to portfolio optimization... And third, a $2.5 billion related charge principally to broad restructuring and other actions including contract reassessments, real estate rationalization, and workforce reductions. Of note, approximately $625 million of this charge relates to a loss contract reserve for third party contractual relationships within the Optum portfolio that are structurally unprofitable and that we could not exit for 2026." — Wayne DeVeydt, CFO

The loss-contract reserve is the most strategically important line: it pre-recognizes the drag from contracts the company is locked into for 2026 but cannot make profitable, taking the pain now rather than bleeding it through the year. The $623M will amortize back as a non-cash add to 2026 GAAP operating earnings, which is why management excludes it from adjusted figures on both sides.

Assessment: This is a textbook kitchen-sink quarter, and it is a feature, not a bug. Finalizing the cyberattack costs closes a two-year overhang, reserving the loss contracts removes a known 2026 drag from the run-rate, and the restructuring rationalizes real estate and headcount the prior regime over-built. The market treated the charge as evidence of how deep the rot ran; we treat it as evidence the new team is willing to take the pain up front to guide off a clean base. The cleaner the base, the more credible the floor.

3. Optum Health's Loss and the Path to a ~2.4% 2026 Margin

The Q4 Optum Health loss and the reset of the clean baseline to ~$1.5 billion are the genuine bad news of the print, and management neither hid nor dressed it up. The 2026 plan rebuilds off the lower base toward a positive ~2.4% margin, with the long-term 6–8% target reaffirmed but explicitly deferred.

"We expect operating earnings growth of approximately 9% while expanding margins by approximately 30 basis points. This growth is driven by a back to the basics focus on integrated value based care and execution... we now have nearly 100% of our employee provider groups on one of three strategic electronic medical records. This is down from 18 EMRs in the past few years." — Patrick Conway, Optum CEO

The COO grounded the confidence in operating evidence rather than promises: roughly 30% of mature value-based-care cohorts already perform inside the long-term target range, and named markets (Texas, 750,000 patients) already deliver target-range margins with total cost of care ~30% below competitors. The fix is narrower network, cleaner risk book, consistent execution, and cohort maturation.

Assessment: The honesty is the asset here. Management could have buried the baseline reset; instead it named the new ~$1.5 billion figure and built the 2026 guide off it. A ~2.4% guided margin off a clean base is a far more underwritable proposition than the deteriorating ~$3 billion run-rate that turned out to be illusory at Q3. The recovery is still multi-year and the absolute ceiling is lower than we thought, but the starting line is now real. This remains the swing factor for the multi-year case, and it is finally being measured from a floor rather than a moving target.

4. Medicare Advantage Repricing and the 1.3–1.4 Million Exit

The core 2026 margin lever is the aggressive Medicare Advantage repricing and the deliberate membership contraction it drives. Management now expects a 1.3–1.4 million total MA contraction, larger than the ~1 million guided at Q3, as competitive annual-enrollment shopping intensified, and frames it as a margin-over-membership trade.

"We now expect UHC Medicare Advantage contraction will be in the range of 1.3 million to 1.4 million members for the full year including group, individual, and dual special needs plans. These are greater losses than originally anticipated as competitive market dynamics drove higher than expected plan shopping during the intensely competitive annual enrollment period. Our 2026 approach favored margin recovery and these membership trends are a result of these actions." — Timothy Noel, UnitedHealthcare CEO

Management priced individual Medicare Advantage to a ~10% trend (versus 2025's ~7.5% actual), expects ~50bp of Medicare margin recovery, and characterized the larger-than-planned membership loss as sitting "within our internal planning range." The 2026 book is repriced for sustainability rather than growth.

Assessment: A larger MA contraction than guided three months ago is, paradoxically, a sign of discipline rather than failure: the company held price into a competitive enrollment season and let members walk rather than chase share at a loss. Pricing to 10% trend builds in conservatism against the 7.5% actual. The cost is a smaller, slower-growing book and a shrinking top line, which is precisely why the revenue guide declines. We would rather own a repriced, profitable franchise than a growing, money-losing one, and the willingness to lose 1.4 million members for margin is the clearest evidence the pricing discipline is real.

5. The 2026 Revenue Decline and the Right-Sizing Strategy

The revenue guide of more than $439 billion, down ~2%, is the single biggest break from the prior narrative and the proximate cause of the sell-off. Management framed it not as weakness but as a deliberate enterprise right-sizing: shedding unprofitable membership, exiting non-core geographies, and refocusing on the integrated value-based-care core.

"2026 revenues are projected to exceed $439.0 billion, a 2% year-over-year decline reflecting planned right-sizing across the enterprise." — UnitedHealth Group 2026 outlook, per the earnings release

The decline aggregates the deliberate UnitedHealthcare membership cuts (2.3–2.9 million medical lives), the Optum Health right-sizing to ~4.1 million accountable patients, the South American and other business exits, and the Optum Rx script attrition flowing from UnitedHealthcare. It is a smaller company on purpose.

Assessment: This is where reasonable investors split. The bear reads a shrinking top line as a broken growth engine and a permanently lower earnings base. We read it as the necessary consequence of pricing for margin instead of share: you cannot reprice aggressively, shed 2.9 million members, and exit unprofitable contracts without the revenue line falling. A franchise that shrinks revenue 2% while guiding margin and EPS up is choosing profitability over optics. The narrative cost is real, the "return to growth in 2026" story is dead, but the quality of the remaining earnings is higher, not lower.

6. Wayne DeVeydt as CFO and the Finance-Credibility Reset

The finance function's credibility is itself a thesis variable after a year of suspended and missed guidance, and Q4 was the first full guide authored by permanent CFO Wayne DeVeydt, installed at Q3. He owned both the FY2025 results and the entire 2026 outlook, a notable step up from Q3's deferral to "current consensus."

"UnitedHealth Group's 2026 outlook reflects a business delivering durable performance improvement and margin expansion through greater operating discipline and precise execution... we expect leverage to continue improving through the year... and to reach our long term debt to capital target of approximately 40% before year end." — Wayne DeVeydt, CFO

His framing was quantitative and conservative throughout: slightly under two-thirds of 2026 earnings in the first half, MCR seasonality below the midpoint in H1 and above in H2, ~$1 billion of operating-cost reductions (many AI-enabled), and a debt-to-capital target reaffirmed for before year-end 2026.

Assessment: A permanent CFO authoring a beatable, fully-specified first guide is exactly the credibility signal the franchise needed, and the sandbagged construction is a feature of a finance team that intends to beat-and-raise rather than guide-and-cut. The contrast with the 2024 over-promising regime is stark. We weight the change positively: the most reliable tell of a turnaround is a finance function that under-promises its first full year, and that is what we got.

7. Capital Allocation, the 40% Target, and the Protected Dividend

The capital posture stayed defensive but with a clearer light at the end of the deleveraging. Debt-to-capital ended 2025 at 43.9% (from 44.1% at Q3), and management reaffirmed the long-term 40% target for before year-end 2026, after which historical capital deployment resumes in the second half. The 2026 plan funds ~$8 billion of dividends, a modest ~$2.5 billion of buyback, and ~$3.8 billion of capex.

"For 2026, we expect our dividend to remain well supported by earnings and cash flow... we expect to reach our long term debt to capital target of approximately 40% before year end. And as this progress continues, we expect to return to our historical capital deployment practices in the second half of the year." — Wayne DeVeydt, CFO

Full-year operating cash flow was $19.7 billion, 1.5x net income and ahead of plan on timing, against $5.5 billion of buybacks and $7.9 billion of dividends in 2025. The 2026 plan keeps cash conversion near 1.1x net income.

Assessment: Reaffirming the 40% target for year-end 2026, with a modest $2.5 billion buyback already penciled into the guide, signals the deleveraging is on schedule and the buyback restarts on the horizon rather than indefinitely paused. The protected dividend and 1.5x cash conversion keep a hard floor under the stock at the washed-out price. The buyback is small in 2026, so next year's EPS recovery is still an operating story, but the capital posture is one notch less defensive than at Q3, and at ~$283 the resumed buyback compounds against a much lower share price.

8. The Transparency Push and Independent Business-Practice Reviews

Management devoted significant prepared-remarks airtime to a transparency and independent-oversight initiative, a direct response to the public and regulatory scrutiny the franchise has absorbed. The first independent reviews of business practices were published in December, with remediation due by March and recurring public disclosure planned.

"We are methodically taking steps to advance greater trust and transparency wherever we serve the public health care interests. This began with the independent reviews of business practices and risk assessment in pharmacy services, and in care management. Those first independent reports were published in December... in 2026, we will begin to publish our results in areas of interest such as prior authorizations, and claim approval rates." — Stephen Hemsley, Chairman & CEO

Management characterized the December reviews as "very positive," focused on controls, oversight, and governance, with 2026 reviews turning to risk-assessment accuracy and clinical-policy accuracy, areas that bear directly on the Medicare Advantage billing questions at the heart of the regulatory overhang.

Assessment: A proactive transparency program is smart positioning ahead of regulatory and political pressure, and turning the 2026 reviews toward risk-assessment accuracy is a tacit acknowledgment of where the scrutiny is pointed. It does not resolve the DOJ tail, and self-commissioned reviews are not a substitute for the government's own conclusions, but it is the kind of credibility-rebuilding gesture that can shape the political environment at the margin. We treat it as a modest positive for the regulatory narrative, not a resolution of it.

9. DOJ, the CMS 2027 Advance Notice, and the Regulatory Overhang

The regulatory picture is the live offset to the bull case, and it darkened on the print day. Management again offered no direct commentary on the reported DOJ civil and criminal Medicare-billing investigations, which remain a listed risk factor. Separately, and more concretely, the CMS 2027 Medicare Advantage advance notice published the night before the call carried a growth rate management called far too low.

"The news that we received last night in the advance notice was disappointing... it's a further [cut] for a program that has experienced $130 billion in funding reductions over the last three years under the prior administration... it will mean very meaningful benefit reductions and will once again need [us] to take a hard look at our geographic footprint, our product footprint." — Timothy Noel, UnitedHealthcare CEO

The advance notice is preliminary and subject to a final rate, and management committed to working with CMS, but it signals 2027 could rhyme with 2026: more repricing, more benefit cuts, more membership contraction. The DOJ investigations remain entirely unquantified.

Assessment: This is the reason the upgrade is to Outperform and not to high-conviction Outperform. The DOJ tail is unquantifiable and unresolved, and the soft 2027 advance notice means the funding headwind is not a one-year event. We are explicit that we are not calling the bottom on the regulatory or funding environment, which may stay hostile into 2027. We are calling the bottom on expectations and valuation, which is a different and more tractable judgment. The regulatory overhang caps the upside; it does not, at ~16x a beatable floor, justify pricing the franchise for permanent impairment.

10. The AI and Operating-Efficiency Agenda

Running underneath the segment guides is an aggressive AI-driven cost program management is counting on for the margin inflection. The company plans to invest nearly $1.5 billion in technology in 2026, targeting ~$1 billion of operating-cost reductions, many AI-enabled, with the operating cost ratio guided to 12.8% ±50bp.

"We anticipate operating cost reductions of nearly $1 billion in 2026, many AI enabled and importantly in higher customer experience and satisfaction at a lower cost. Over 80% of calls from members leverage AI tools to help answer members' questions faster and more accurately." — Timothy Noel, UnitedHealthcare CEO

Management tied the AI program to both UnitedHealthcare service efficiency and the Optum Insight product roadmap, framing AI as the lever that funds reinvestment while still improving the cost ratio.

Assessment: The ~$1 billion AI-enabled cost target is credible directionally and is already embedded in the 12.8% operating-cost-ratio guide, so it is not incremental upside to the guide so much as a pillar holding it up. It is the softest of the 2026 levers (cost programs slip), but it is also the one with the most multi-year optionality if the Optum Insight platform ambitions land. We do not underwrite the AI savings as a beat driver; we note them as the mechanism by which a conservative cost-ratio guide stays achievable while reinvestment continues.

Guidance & Outlook

The 2026 outlook is the print. It is the company's first fully-specified full-year guide since the May 2025 suspension, authored by a permanent CFO, and built on "greater than" floors across every line. The shape is a smaller, more profitable enterprise: revenue down ~2%, operating earnings up to greater than $24 billion, net margin recovering toward ~3.6% from 2.7%, and adjusted EPS greater than $17.75.

The segment build supports the floor. UnitedHealthcare guides to revenue greater than $335 billion and operating earnings greater than $10.8 billion (~3.2% margin, +40bp), Optum to revenue greater than $257.5 billion and operating earnings greater than $13.2 billion (~5.1% margin). Within Optum: Optum Health greater than $91 billion revenue and greater than $2.2 billion earnings (~2.4% margin) with ~4.1 million accountable patients; Optum Insight greater than $21 billion and greater than $4.75 billion (Optum Financial folded in); Optum Rx greater than $150.5 billion and greater than $6.25 billion on scripts above 1.52 billion. Capital allocation funds ~$8 billion of dividends, ~$2.5 billion of buyback, and ~$3.8 billion of capex.

First-half / second-half shape: Management guided slightly under two-thirds of full-year earnings to the first half, with MCR notably below the midpoint in H1 and above in H2, consistent with 2025 seasonality and the Inflation Reduction Act Part D mechanics. That puts the implied H1 adjusted EPS near ~$11.50 of the >$17.75 floor.

Street at: The Street carried ~$454.6 billion of 2026 revenue and an adjusted-EPS recovery toward ~$20 into the print. The guide sits ~$15.6 billion (~3.4%) below on revenue and roughly 10%+ below on EPS, which is the entire reason the stock fell 19.6%. The gap is real, but it is a gap to an expectation the company never authored: at Q3 management pointed the Street to "current consensus" without owning it, and the Street built the recovery itself.

Guidance style: Conservative and floor-based to the point of sandbagging. Every figure is a "greater than," the revenue base is deliberately right-sized for cleanliness, the margin path (88.8% MCR, +40bp segment margins) is achievable against the repricing math, and the H1-weighting front-loads the visible earnings. This is the guide of a new finance team that wants to beat-and-raise through 2026, the opposite of the over-promising that broke credibility in 2024. The style tells you the floor is real; it deliberately understates the true earnings power.

Analyst Q&A Highlights

Whether Medicare Advantage Has Bottomed and Its Importance to the Enterprise

The opening exchange pressed on whether 2026 marks the bottom of the Medicare Advantage cycle and how central the MA book is to the rest of the franchise, especially Optum Health. Management declined to call a 2027 margin bottom given the same-morning advance notice but stressed the integration logic runs both ways.

Q: "You're guiding to a decline in 2026 in traditional MA lives of even more than that, so almost mid teens... Do you think we're at the bottom of the MA cycle now? Should we expect MA margins to improve not just what you mentioned in '26, but in 2027? And then if you could help frame how important that core MA book is to the other segments of the enterprise, especially OptumHealth."
— Josh Raskin, Nephron Research

A: "Our strategy in '26 did focus more so on margin than it did on any specific membership target... we feel good about our margin recovery efforts of about 50 basis points across Medicare Advantage. The membership losses, while they're a little north of what we were talking about earlier, really kind of sit within our internal planning range... moving into 2027, the news that we received last night in the advance notice was disappointing."
— Timothy Noel, UnitedHealthcare CEO

Assessment: Management's refusal to quantify 2027 while the advance notice is unsettled is the honest answer, and it is also the crux of why this is a measured Outperform rather than a high-conviction one. The 50bp of 2026 MA margin recovery within a planned membership decline is bankable; 2027 is hostage to a CMS rate that just came in soft. The integration framing (MA matters to Optum, and Optum's complementary value matters to all payers) is the standing bull pillar, and it neither strengthened nor broke this quarter.

The Fourth-Quarter Optum Health Shortfall and 2026 Stability

The most pointed exchange of the call dissected the Optum Health Q4 miss against the Q3 framing and demanded a reason to trust the 2026 guide given the volatility. Management conceded the miss, attributed it to restructuring and one-time items, and reset the clean baseline.

Q: "You guided to just under $3 billion of OI with the third quarter results. And if I'm doing the adjusted math correctly, [it] came in closer to $2.3 billion. So [it] underperformed by $600[M] of OI in the fourth quarter. It's fairly surprising to still see this kind of volatility in the business... what gives you guys confidence in more stable performance in 2026?"
— Justin Lake, Wolfe Research

A: "Your results in the fourth quarter and for the full year were slightly disappointing to our expectations. But really reflective of the restructuring actions that we took in the fourth quarter as well as some onetime items that are now right behind us... excluding restructuring and the move of Optum Financial, our adjusted earnings are now approximately $1.5 billion which is our new baseline that we will continue to build off of in the future."
— Krista Nelson, Optum Health COO

Assessment: This is the exchange that did the damage, and management did not flinch from it. The ~$1.5 billion baseline is materially below the ~$3 billion the Street extrapolated from the Q3 guide, a genuine downward reset of the multi-year earnings ceiling. The constructive read is that the baseline is now grounded in a cleaned-up book rather than a deteriorating one, but the candor cuts both ways: the company conceded its own Q3 framing was too high, which is the strongest single argument for the bears.

The 2027 Coding Components and Optum Health's Long-Term Margin

A line of questioning probed the coding-related pieces of the 2027 advance notice and whether they threaten the 6–8% Optum Health margin target. Management said its exposure is in line with the industry and reaffirmed the long-term target on execution evidence.

Q: "If you take out normalization... the risk model and another 1.5 for charts, so it's like a 3.3% headwind... Would you expect a similar dynamic with these two coding components that, as a company who's probably better than average at coding, you'd see more than this kind of 3.3% headwind? And do you still feel good about getting to a 5% margin in value based care OptumHealth?"
— Kevin Fischbeck, Bank of America

A: "We don't expect the impact to be different for us versus the rest of the industry on those two elements... Our modeling shows consistency between what we're seeing and also what the estimates are of industry averages... about 30% of our mature value based care patients that are already inside that target margin range or above. And so those two examples... give me a lot of confidence in the runway ahead for OptumHealth."
— Timothy Noel, UnitedHealthcare CEO; Krista Nelson, Optum Health COO

Assessment: The disclosure that ~30% of mature value-based-care cohorts already sit in or above the 6–8% target range is the most useful piece of evidence for the recovery case, because it makes the long-term target a question of mix migration rather than fundamental fixability. Confirming the company is not disproportionately exposed to the 2027 coding cuts removes a feared idiosyncratic headwind. The runway is execution-dependent and multi-year, but the proof points are real, not hypothetical.

Medicaid Rates and 2026 Margin Posture

A question sought the latest read on Medicaid rate adequacy heading into 2026 and whether the margin assumption had improved. Management guided to continued pressure with rate increases still trailing acuity.

Q: "In the Medicaid business, I think you made reference to getting a little bit of rate relief... if the rates are coming in a bit better, [have you] revisited your margin assumption for the Medicaid business at all in 2026?"
— Steven Baxter, Wells Fargo

A: "For 2026, our view remains unchanged. For Medicaid we do expect some margin contraction due to the ongoing dislocation of rates and continued elevated medical trends... We are projecting rate increases in the range of six to 7% in aggregate for the year, but that will continue to be below our [trend]."
— Wayne DeVeydt, CFO

Assessment: Medicaid stays the weak link, with 6–7% rate increases still trailing trend and margin guided to contract further in 2026. The honesty that the view is "unchanged" rather than improving is consistent with the company calling Medicaid a 2026 trough with recovery deferred. It is a known headwind already in the guide, not a fresh surprise, but it is a reminder the 2026 inflection is led by Medicare repricing and Optum, not the government book broadly.

OptumRx Client Wins and the Backfill of UHC Attrition

Questioning sought to understand the 800-plus new Optum Rx client wins and whether they offset the membership lost through UnitedHealthcare's contraction. Management framed a strong selling season that backfilled more than half the UHC loss.

Q: "When we think about OptumRx, you talked about the member contractions because of what happened on the United side, but 800 new clients on that side... Can you just talk about those [800] new clients and if there's anything different that you're seeing in them as we think about [2026]?"
— Lisa Gill, JPMorgan

A: "Strong selling season in 2026 combined with retention allowed us to backfill... about half, maybe more than half, of the membership loss from UHC. And so that puts us in a nice position to deliver a modest 2% earnings growth in 2026... the reason we're winning [is] threefold, affordability, transparency, and execution."
— Wayne DeVeydt, CFO

Assessment: Backfilling more than half of a forced intercompany attrition with external wins is genuine commercial validation that Optum Rx competes on its own merits, not just as captive UHC volume. The transparency-led pitch (100% rebate pass-through, removed reauthorizations) is resonating ahead of regulatory pressure. It keeps Rx a dependable mid-single-digit grower and confirms the PBM is a competitive asset rather than a captive cost center, even if its margin remains structurally capped.

Commercial Membership Decline and Exchange Margin

A question sought the breakout of the 1.3–1.4 million commercial risk-life decline and the 2026 margin path for group and the ACA exchanges, where the company has pledged to rebate profits. Management split the decline and reframed the exchange book.

Q: "Could you just provide us with the breakdown of the 1.3 million to 1.4 million commercial risk lives that you're expecting to decline in 2026, how that breaks out between commercial group and then the exchanges? And also just in terms of margins year over year progression for commercial group and the exchanges."
— Scott Fidel, Goldman Sachs

A: "On membership pertaining to the risk based decline, the largest share of that membership decline is connected to our exchange business for 2026... 500,000 plus attributable to the exchange business, the remainder to those three factors... I expect us to close more than half of the gap between our 2025 margin performance and our historical [group] margin range, which we expect to achieve in 2027."
— Dan Schumacher, UnitedHealthcare

Assessment: The willingness to shed 500,000-plus exchange members and run that book to a barely-positive ~1% margin while pledging to rebate ACA profits confirms the company is exiting unprofitable growth rather than defending it. Closing more than half the group-margin gap in 2026 with the balance in 2027 is the same every-segment-turns-in-2026-fully-heals-in-2027 cadence that runs through the whole guide. It is disciplined and it is slow, which is exactly the profile of a beatable floor.

What They're NOT Saying

1. A quantified 2027 outlook: Management explicitly declined to discuss 2027 margins or membership, citing the unsettled CMS advance notice. After framing 2027 as the real acceleration year for four quarters, the refusal to put any number on it, on the very day a soft rate notice dropped, leaves the multi-year recovery thesis formally unanchored beyond 2026.
2. The DOJ exposure: For the third consecutive quarter, not a word of direct commentary on the reported civil and criminal Medicare-billing investigations beyond the boilerplate risk factor. The transparency push toward risk-assessment-accuracy reviews implicitly acknowledges where the scrutiny points, but the magnitude, timeline, and potential remedies remain entirely unquantified, the single largest tail risk still unaddressed.
3. How conservative the >$17.75 floor really is: Management wrapped every 2026 figure in "greater than" language but never characterized the degree of conservatism or offered a point estimate or range. A floor with no stated cushion is, by design, a number the company intends to beat without telling you by how much, which is the right posture for credibility-rebuilding but leaves the true 2026 earnings power undefined.
4. The absolute size of the Optum Health 2027 recovery: The ~$1.5 billion clean 2025 baseline and the ~2.4% 2026 guide are specified, and the 6–8% long-term target is reaffirmed, but management gave no bridge for how and when the segment gets from ~2.4% to the target, only that it is "multi-year" and execution-dependent. The shape of the most important recovery in the franchise is still a sketch.
5. Succession beyond Hemsley: A year into the restart under a 73-year-old chairman-CEO, the call again offered no view on long-term leadership succession. For a recovery management itself frames as a 2027-and-beyond story, the standing governance gap remains unaddressed.
6. Whether the right-sizing is finished: Management framed the 2026 revenue decline as deliberate "right-sizing," but did not say whether 2026 is the bottom of the shrinkage or whether further membership and revenue contraction follows in 2027 if the CMS rate stays soft. A franchise guiding its first revenue decline in three decades without committing to a return to growth leaves open whether this is a one-year reset or a multi-year contraction.

Market Reaction

• Pre-print setup: UNH closed at $351.64 on January 26, entering the before-open print up 6.5% year-to-date (from $330.11 at 2025 year-end) and up 6.0% over the trailing 30 days, but still down 35.3% over the trailing twelve months (from $543.52 a year earlier). The 52-week closing range was $237.77 to $599.47, so the stock entered well off its July lows but deep in its one-year range. The S&P 500 was up 1.5% YTD.
• Reaction (January 27 session): The stock gapped down 16.4% to open at $293.97, traded an intraday range of $280.40 to $299.50, and closed at $282.70, down 19.6% (−$68.94) on the day, one of the steepest single-session declines in company history. Volume was 65.8 million shares versus a 6.5 million 30-day average, 10.1x normal. The S&P 500 closed up 0.4%, so the decline was entirely idiosyncratic, a ~20-point relative move against a flat-to-up tape.

The 19.6% capitulation was a verdict on the 2026 outlook, not the printed quarter. Three things compounded into the move. First, the revenue guide of more than $439 billion sat ~$15.6 billion below the ~$454.6 billion Street number and walked back the "return to growth" narrative, the first annual revenue decline in over three decades, which is a narrative shock for a stock long owned as a reliable compounder. Second, the adjusted-EPS floor of more than $17.75 landed roughly 10%-plus below the ~$20 recovery estimates carried in, repricing the entire 2026 base lower in a single morning. Third, the near-zero GAAP quarter and the $2.8 billion Optum Health operating loss underlined how deep the reset ran, and the same-morning soft CMS 2027 advance notice removed the "2027 acceleration" cushion the bulls were leaning on. At the $282.70 close the stock trades around 16x the more than $17.75 floor, a multiple that prices the franchise as if the impairment were permanent. We read the move as forced de-positioning into a sandbagged guide, the classic shape of a washout that overshoots the fundamentals.

Street Perspective

Debate: Is the Soft 2026 Guide a Broken Franchise or a Sandbagged Floor?

Bull view: The bull case holds the guide is deliberately low: a new CFO's first full-year outlook after a credibility crisis, wrapped in "greater than" language, with revenue right-sized down so the base is clean and the loss contracts reserved out. The 88.8% MCR and +40bp segment margins are achievable against the repricing math, setting up beat-and-raise through 2026.

Bear view: The bear camp counters that a 2% revenue decline is a structural break, the first in three decades, that the ~$1.5 billion Optum Health baseline reset proves the Q3 framing was illusory, and that an 8.6% EPS growth floor off a depressed base is simply a weak number dressed up as conservatism. Management has missed before; "greater than" is not a guarantee.

Our take: The bulls have the better read, and the price makes it actionable. Every structural tell of a sandbagged guide is present: a clean right-sized base, "greater than" floors, an H1-weighted shape, and a margin path that is conservative against repricing. The bears are right that the Optum Health reset lowers the ceiling and that revenue is genuinely shrinking, but at 16x a beatable floor the market is paying for permanence in a number built to be exceeded. We would rather own the sandbag than short it.

Debate: Has the Stock Overshot to the Downside?

Bull view: The optimistic view is that a 19.6% single-day drop to ~$283, ~16x a low-bar floor, on forced de-positioning, is the textbook overshoot. The dividend is protected at 1.5x cash conversion, the buyback restarts in H2 2026 against a far lower share count, and any beat-and-raise through the year re-rates the multiple off a washed-out base.

Bear view: The skeptics argue 16x is not cheap for a franchise with shrinking revenue, a 2.4% Optum Health margin, an unquantified DOJ tail, and a soft 2027 rate notice that means the funding headwind is not a one-year event. Value traps are cheap for a reason, and a falling top line caps the multiple regardless of the floor.

Our take: The bulls win on risk/reward at this price, with eyes open. We held Hold through the ~40% rally specifically to keep powder for a washout, and a 19.6% capitulation to 16x a sandbagged floor is the entry we were waiting for. The bears are correct that this is not a clean growth story and that the DOJ tail is real, which is why this is an Outperform on de-risking and valuation, not on fundamentals. But "cheap with an overhang" at a washed-out price is a materially better proposition than "fairly valued after a rally," which is where we sat at Q3.

Debate: Can Optum Health Be Rebuilt Off the $1.5 Billion Baseline?

Bull view: The bull case is that the deck is now clear: the loss contracts are reserved, the network is narrowed ~20%, risk membership is cut ~15%, the book is consolidated onto three EMRs, and ~30% of mature cohorts already perform inside the 6–8% target. A clean ~$1.5 billion base growing ~9% in 2026 toward a positive ~2.4% margin is a real, gradeable recovery.

Bear view: The bear view is that resetting the baseline a third of the way below the Q3 framing is an admission the segment was never as healthy as claimed, that a 2.4% guided margin is multiple years from the 6–8% target, and that two-thirds of the value-based book serving UnitedHealthcare makes much of the "moat" intercompany rather than external.

Our take: The bears are right that the ceiling came down, and we have lowered our own multi-year Optum Health earnings assumption accordingly. But the bulls are right that the starting line is finally real: a clean baseline beats a deteriorating run-rate, and named target-range markets prove the model works where execution is consistent. We treat Optum Health as a 2027 call option on a now-cleaner base, with the proof points (mature-cohort margins, network rationalization) gradeable quarter by quarter. It is the part of the thesis most likely to surprise in either direction.

Model Update Needed

Valuation impact: At the $282.70 reaction close against the more than $17.75 2026 adjusted-EPS floor, the stock trades around 16x current-year adjusted earnings, down from ~22.6x at the Q3 print and back toward the ~16x crisis level of late July 2025, despite a business that has since cleared its deck, reserved its loss contracts, and guided to margin expansion. We see the multiple as detached from the fundamentals on the downside. On a sandbagged floor that we expect to be beaten toward ~$18.00–$18.75, with a protected dividend, a buyback resuming against a far lower share count, and a 2027 acceleration still ahead (now with more regulatory uncertainty), the de-risked earnings no longer carry the rally premium they did at Q3. We see asymmetric upside from current levels: the expectations reset is complete, the floor is beatable, and the next leg requires only that management deliver the beat-and-raise the guide was built to enable, or that the DOJ tail clarifies favorably. The live downside is a DOJ escalation or a 2027 rate cut deeper than feared; we size the upgrade to reflect that the overhang is real but, at 16x a floor, more than priced.

Thesis Scorecard Post-Earnings

We grade this quarter against the standing thesis carried since our Q2 initiation. The pillars are unchanged; the status tags move with what the print and call revealed.

Overall: The thesis re-balanced rather than simply strengthened or weakened. The repricing bear point is now flowing through to a guided margin improvement (Bear-1 eased), and the valuation pillar re-opened decisively as the washout restored the crisis-cheap dislocation (Bull-3 improved). Against that, the return-to-growth bull pillar bifurcated, with the revenue leg walked back, and the regulatory bear point escalated on the soft 2027 notice. The net is a cheaper, cleaner, smaller franchise with a beatable floor and a live but priced-in overhang, which is a better risk/reward than the fairly-valued-after-a-rally setup we faced at Q3.

Action: Upgrade to Outperform from Hold. We maintained Hold through the ~40% rally off the July lows precisely to keep dry powder for a capitulation, and the 19.6% washout to ~$283 (~16x a sandbagged >$17.75 floor) is that entry. The deck is cleared, repricing is in the numbers, and the risk/reward has turned asymmetric. We are explicit that this is a call on expectations bottoming, not fundamentals: revenue is shrinking, Optum Health's ceiling is lower, and the DOJ tail plus a soft 2027 rate notice are unresolved. We would revisit Hold if the DOJ exposure quantifies materially or the 2027 rate environment deteriorates further, and would revisit Underperform only if management cuts the 2026 floor or the Optum Health baseline resets lower again. But at 16x a floor built to be beaten, the franchise is priced for a permanence we do not believe, and the contrarian discipline that held through the rally is now rewarded with the better entry it was waiting for.